Digital Biomarkers Market, By Type (Sensors, Wearable, Mobile based Applications, and Others), By Clinical Practice (Monitoring digital biomarkers, Diagnostic digital biomarkers, Predictive & Prognosis digital biomarkers, and Others), By Therapeutic Area (Neurological disorders, Cardiovascular diseases, Sleep & Movement disease, Diabetes, Respiratory disorders, and Others), By End-Users (Healthcare Providers, Payers, Biopharmaceutical Companies, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Digital Biomarkers Market was valued at US$ 4.8 Billion in 2024 and is projected to grow at a CAGR of 26.40% to reach US$ 40.1 Billion by 2034.

Digital biomarkers are objective and quantifiable physiological and behavioral data collected and measured through digital services such as wearable, portables, digestible, and implants. Collected data is used to influence, explain, or predict health-related outcomes. Digital Biomarkers are also modular, non-invasive, and cheaper to measure.

Surge in usage of smartphones and wearable devices has become a significant factor in the expansion of target market. Digital biomarkers have shifted healthcare from a reactive to a more proactive mode. The spread of wearable digital technologies in healthcare and huge investment in research and development activities have contributed to digital biomarkers market growth. The COVID-19 pandemic has increased rapid digitalization in healthcare sector, which led to rise in research and funding for digital biomarker driven drug discovery, which is expected to drive growth in the Digital Biomarkers Market. 

Adoption of digital devices and health-related mobile applications is the major factor to foster the target market. As digital biomarkers support various diagnostic and prognostic assessments in different illness areas such as diabetes, cardiovascular disease, and neurological disease, investment in digital biomarkers by emerging players is increasing which is expected to drive the target market growth.

For instance, in 2023, Huma, Camden Health Partners and UCL Partners has launched its digital health programme in North Central London for people to identify and manage cardiovascular disease. Newly launched digital health programme has aimed to prevent heart attacks, and strokes, to expand primary care capacity by adoption of digital tools, and to provide advance proactive and predictive care for people who are at risk of world’s leading cause of death.

Restrains:

A lack of clinical and analytical validity evidence to support digital biomarkers is expected hinder market growth. As the device could differ the details of measurement, which would require more trials to gain satisfactory result to include digital biomarkers as secondary or exploratory outcomes.

Digital Biomarkers Market is segmented based on type, clinical practice, therapeutic area, end-users, and region.

Type Insight

On the basis of Type, the Digital Biomarkers market is segmented into Sensors, Wearable, Mobile-based applications, and others. Mobile-based applications have dominated target market growth because of the growing adoption of smartphones in healthcare industries.

Example: In June 2021, Epillo has launched world’s new unique integrated healthcare mobile application which works with machine learning, artificial intelligence, and block-chain. Newly launched application is developed for service providers, patients, and for healthcare practitioners.

Clinical Practice Insights

On the basis of Clinical Practice, the Digital Biomarkers market is segmented into Monitoring Digital Biomarkers, Diagnostic Digital Biomarkers, Predictive and Prognosis Digital Biomarkers, and others. Due to increased investment in smart-watches and wearable technologies to provide more accurate access to health-related information, monitoring digital biomarkers is dominating the target market growth.

Therapeutic Area Insights

On the basis of Therapeutic Area, the Digital Biomarkers market is segmented into Neurological Disorders, Cardiovascular Diseases, Sleep and Movement Disorders, Diabetes, Respiratory Disorders, and others. Cardiovascular diseases have dominated the target market growth because of the soaring prevalence of chronic conditions due to an unhealthy lifestyle.

For instance, according to CDC (Centers for Disease Control and Prevention) about 697,000 people in US died from heart disease in 2020.

For instance, according to CDC (Centers for Disease Control and Prevention) one person dies at every 34 seconds in US from cardiovascular disease.

End-Users

On the basis of End-Users, the Digital Biomarkers market is segmented into Healthcare Providers, Payers, Biopharmaceutical Companies, and others. Biopharmaceutical companies is expected to show significant market share in the target market, as biopharmaceutical companies use wearable’s for improving their internal processes of understanding or tracking the patient for various factors such as sweat analysis, glucose monitoring, electro-stimulations and pressure sensors.

Regional Insights:

On basis of region the Digital Biomarkers Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period. Moreover, rising prevalence of chronic diseases, presence of major key players, implementation of new technologies, FDA approved digital devices, is anticipated to increase demand for Digital Biomarkers in the region.

Attribute	Details
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Type - Sensors, Wearable, Mobile based Applications, and others By Clinical Practice - Monitoring digital biomarkers, Diagnostic digital biomarkers, Predictive & Prognosis digital biomarkers, and others By Therapeutic Area - Neurological disorders, Cardiovascular diseases, Sleep & Movement disease, Diabetes, Respiratory disorders, and others By End-Users - Healthcare Providers, Payers, Biopharmaceutical Companies, and others
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Digital Biomarkers Market report based on type, clinical practice, therapeutic area, end-users, and region:

Digital Biomarkers Market, By Type:

• Sensors
• Wearable
• Mobile based Applications
• Others

Digital Biomarkers Market, By Clinical Practice:

• Monitoring digital biomarkers
• Diagnostic digital biomarkers
• Predictive & Prognosis digital biomarkers
• Others

Digital Biomarkers Market, By Therapeutic Area:

• Neurological disorders
• Cardiovascular diseases
• Sleep & Movement disease
• Diabetes
• Respiratory disorders
• Others

Digital Biomarkers Market, By End-Users:

• Healthcare Providers
• Payers
• Biopharmaceutical Companies
• Others

Digital Biomarkers Market, By Region:

 

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Digital Biomarkers Market includes,

• Koneksa

Koneksa, a leading player in development of digital biomarker. Koneksa’s digital biomarkers are used across healthcare for accelerating development of new medicines & to improve understanding of disease.

• Bayer AG

Bayer AG, largest pharmaceutical companies in the world which provides innovative solutions to prevent, and treat diseases. Bayer is also specialized in digital biomarkers, veterinary products and chemicals.

• Biogen Inc.

Biogen Inc., world’s first global biotechnology companies, specialized in discovery and development of therapies in treating neurological diseases. Biogen Digital Health a unit of Biogen provides personalized & digital medicine in neuroscience.

• Pfizer Inc.

Pfizer Inc., pharmaceutical & biotechnology company which is a developer and producer of vaccines and medicines for oncology, cardiology, immunology, neurology, immunology, endocrinology, etc.

• F. Hoffman-La Roche Ltd.

F. Hoffman-La Roche Ltd., Swiss multinational healthcare company operates under two sectors like diagnostics and pharmaceuticals. It has become the fifth largest pharmaceutical company in the world with leading provider of cancer treatments worldwide. Roche is the world’s largest spender in pharmaceutical research & development.

• Amgen Inc.

Amgen Inc., worldwide pioneer in biotechnology. The company is focused on biochemistry, and molecular biology to provide healthcare business based on recombinant technology.

• AliveCor Inc.

AliveCor Inc., offers AI enabled machine learning powered ECG sensors which deliver medical heart data at anywhere, anytime. The company’s digital tools help patients to access, manage and share their data to connect with cardiologists.

• ActiGraph LLC.

ActiGraph LLC. a leading provider of medical grade wearable technology. The company’s biosensor solutions has been deployed in hundreds of clinical drug trials.  The company believes in developing new technologies to stay at forefront of digital biosensor data movement.

• Altoida Inc.,

Altoida Inc., provides digital biomarker technology to understand health of brain early. The company’s augmented reality platform help in delivering robust measurement of cognitive & functional brain health across 13 unique neurocognitive domains.

• Vivo Sense

Vivo Sense a developer and validater of real-world digital clinical measures, and also provides end to end services and solutions for delivery in clinical trials. The company provides new class patient centric measures which are meaningful to patients, and clinically relevant & sensitive to treatment benefits.

Recent Development:

• In October 2022, Koneksa has launched clinical pipeline of validated digital biomarkers for accelerating life sciences research. Newly launch clinical pipeline is focused on oncology, neuroscience, respiratory and other areas. Koneksa’s 15 digital biomarker programs are in development with upcoming trials.
• In January 2022, Abbott has announced the developing of new consumer biowearable ‘Lingo’ which is designed for tracking signals in the body like glucose, lactate, and ketones by sensor technology and thus will help the people to understand better about general health and take action.
• In August 2022, Medtronic plc, has announced the partnership with BioIntelliSense for exclusive U.S. distribution of multi-parameter wearable used for continuous patient monitoring from in-hospital to home. Biobutton wearable offers upto 1,440 vital signs measurements for daily monitoring patients. HealthCast intelligent patient manager portfolio is designed for visualization, connectivity, and remote patient monitoring.
• In September 2022, Apple Inc., has launched the new design ‘Apple Watch Ultra’ with wide range of features and has become the incredible tool for endurance athletes. Newly launched product help in delivering most accurate GPS of any Apple Watch to date by providing users most precise distance, route data, and pace for training & competing.
• In September 2021, Labcorp and Medidata has entered into an agreement using Medidata Sensor Cloud. Labcorp has selected Medidata’s Sensor Cloud for expanding decentralized clinical trial capabilities and to enable first-in-kind industrial partnership for discovering digital biomarkers.

• Koneksa*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Bayer AG
• Biogen Inc.
• Pfizer Inc.
• F. Hoffman-La Roche Ltd.
• Amgen Inc.
• AliveCor Inc.
• ActiGraph LLC.
• Altoida Inc.
• Vivo Sense

“*” marked represents similar segmentation in other categories in the respective section